BCRX * Aktienübersicht BioCryst Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen, das orale niedermolekulare und Proteintherapeutika zur Behandlung seltener Krankheiten entwickelt. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
BioCryst Pharmaceuticals, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für BioCryst Pharmaceuticals Historische Aktienkurse Aktueller Aktienkurs US$155.00 52-Wochen-Hoch US$170.00 52-Wochen-Tief US$98.29 Beta 1.77 1 Monat Veränderung 0% 3 Monate Veränderung n/a 1 Jahr Veränderung n/a 3 Jahre Veränderung -39.22% 5 Jahre Veränderung n/a Veränderung seit IPO 127.77%
Aktuelle Nachrichten und Updates
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02 Weitere Updates anzeigen
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
Insufficient new directors Nov 12
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02
BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat) Sep 17
Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer Sep 05
BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO May 15
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO May 10
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 09
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 08
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Apr 17
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022) Feb 27
Forecast to breakeven in 2026 Feb 23
BioCryst Launches Orladeyo (Berotralstat) in Italy Feb 20
BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 13
Forecast to breakeven in 2026 Jan 12
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Jan 06
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) Dec 19
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 Dec 01
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina Nov 29
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO Nov 22
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) Nov 11
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023 Nov 03
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology Oct 28
Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013 Oct 27
BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec Sep 19
Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022) Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Biocryst Pharmaceuticals, Inc. Announces Executive Changes Jul 12
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile May 23
BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 27
BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 10
High number of new directors Dec 07
BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health Nov 29
High number of new directors Nov 16
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy Nov 11
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 02
BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
High number of new directors Oct 03
BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer Sep 15
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva Sep 01
Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients Aug 27
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia Aug 19
BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program Aug 06
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021) Aug 05
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
High number of new directors Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) Jul 02
BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 Jun 23
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 10
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 09
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic Jun 08
Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks Jun 07
High number of new directors May 30
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021) May 06
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022 May 06
European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva Apr 28
High number of new directors Apr 27
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
BioCryst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials Apr 09
High number of new directors Apr 08
Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among Hae Patients Following Long-Term Treatment with Orladeyo Feb 25 BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
BioCryst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
BioCryst Appoints Machelle Sanders to Board of Directors Feb 09
High number of new directors Jan 29
BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022 Jan 12
BioCryst Pharmaceuticals, Inc. Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Jan 09
BioCryst Pharmaceuticals, Inc Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Dec 01
Director recently bought Mex$2.0m worth of stock Nov 26
High number of new directors Nov 22
Independent Director recently sold Mex$899k worth of stock Sep 15
High number of new directors Sep 15
High number of new directors Sep 07
BioCryst Pharmaceuticals, Inc. Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic Aug 26
Senior VP & Chief Business Officer Megan Sniecinski has left the company Aug 14
Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.24 loss in 2Q 2020) Aug 06
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
Director Vincent Milano has joined 3rd company board Aug 03
BioCryst Pharmaceuticals, Inc. Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH Jul 16 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Microcap Growth Index
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO™ (berotralstat) in Germany Jun 04
Independent Director recently sold Mex$1.8m worth of stock May 14
Forecast to breakeven in 2024 May 14 Aktionärsrenditen BCRX * MX Biotechs MX Markt 7D 0% 0% 0% 1Y n/a 0% 0%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie BCRX * im Vergleich zur Branche MX Biotechs abschneidet.
Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie BCRX * im Vergleich zum MX Markt abgeschnitten hat.
Preisvolatilität Is BCRX *'s price volatile compared to industry and market? BCRX * volatility BCRX * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stabiler Aktienkurs: BCRX *Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von BCRX * im vergangenen Jahr zu bestimmen.
Über das Unternehmen BioCryst Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen, das orale niedermolekulare und Proteintherapeutika zur Behandlung seltener Krankheiten entwickelt. Das Unternehmen vermarktet Peramivir-Injektion, einen intravenösen Neuraminidase-Inhibitor zur Behandlung der akuten unkomplizierten Grippe unter den Namen RAPIVAB, RAPIACTA und PERAMIFLU, sowie ORLADEYO, einen oralen Serinprotease-Inhibitor zur Behandlung des hereditären Angioödems. Außerdem entwickelt es BCX10013, einen oralen Faktor-D-Inhibitor für komplementvermittelte Krankheiten.
Mehr anzeigen BioCryst Pharmaceuticals, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von BioCryst Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens? BCRX * grundlegende Statistiken Marktanteil Mex$32.04b Gewinn(TTM ) -Mex$2.50b Umsatz(TTM ) Mex$8.32b
3.9x Kurs-Umsatz-Verhältnis
-12.8x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) BCRX * Gewinn- und Verlustrechnung (TTM ) Einnahmen US$412.58m Kosten der Einnahmen US$197.47m Bruttogewinn US$215.11m Sonstige Ausgaben US$338.93m Umsatz -US$123.82m
Zuletzt gemeldete Gewinne
Sep 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -0.60 Bruttomarge 52.14% Nettogewinnspanne -30.01% Schulden/Eigenkapital-Verhältnis -176.9%
Wie hat sich BCRX * auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2024/12/26 22:14 Aktienkurs zum Tagesende 2024/11/11 00:00 Gewinne 2024/09/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen BioCryst Pharmaceuticals, Inc. wird von 30 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Huidong Wang Barclays Tazeen Ahmad BofA Global Research Dae Gon Ha BTIG
27 weitere Analysten anzeigen 
